Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...

Episode 4 of Gray Areas features a conversation with Rammohan R. Sankaraneni, MBBS, of Allina Health, examining the real ...

The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...

A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including ...

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 ...

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases. A phase 2 trial found liposomal ...

This episode, titled ‘Understanding MG Pathophysiology and Therapeutic Targets,’ features panelists examining how advances in ...

AV-1959R is an investigational amyloid-beta vaccine from Nuravax. The FDA granted it Fast Track designation for preventing Alzheimer disease in cognitively unimpaired people with biomarker evidence of ...

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter. Clene has filed an NDA seeking accelerated ...

FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...

One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...